利奈唑胺治疗ICU耐甲氧西林金黄色葡萄球菌感染的临床评价  

Clinical evaluation of Linezolid in the treatment of MRSA infections in ICU

作　　者：陈畅[1] 张彧[1] 

机构地区：[1]大连医科大学附属第一医院急诊ICU,辽宁大连116021

出　　处：《临床军医杂志》2012年第3期588-590,共3页Clinical Journal of Medical Officers

摘　　要：目的评价利奈唑胺治疗ICU耐甲氧西林金黄色葡萄球菌(MRSA)感染的疗效与安全性。方法回顾性分析我院急诊ICU接受利奈唑胺治疗的42例MRSA感染患者的临床资料。结果 42例MRSA感染患者治愈28例,显效5例,进步6例,无效3例,治疗总有效率78.57%(33/42),不良反应发生率为16.67%。结论利奈唑胺是治疗ICU MRSA感染有效、安全的药物。Objective To evaluate the efficacy and safety of Linezolid in the treatment of methieiUin-resistant staphylococcus aureus （MRSA） infections in ICU. Methods A retrospective analysis of the clinical data was conducted for 42 patients with MRSA infections and treated with Linezolid in ICU of our hospital. Results The results showed that the total effective rate was 78.57% （33/ 42） , among the 42 cases, 28 cases cured, 5 cases had positive responses, 6 cases improved, and 3 cases had no efficacy, the drug-related side effect rate was 16.67%. Conclusion Linezolid is an effective and safe drug for MRSA infections in ICU.

关 键 词：利奈唑胺 耐甲氧西林金黄色葡萄球菌 有效性 

分 类 号：R978.1[医药卫生—药品]